drugset / Trial / NCT02883543
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Phase 3
Unknown
330 enrolled
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
RandomizedParallel-groupOpen-labelTreatment
Summary
Eligible patients are administered with oral icotinib 125mg three times daily for two months, in which responsive patients (partial response and stable disease) are randomized (1: 1: 1) and receive icotinib plus concurrent radiotherapy, or chemotherapy plus concurrent radiotherapy, or icotinib monotherapy.
Timeline
- Start
- 2016-06
- Primary completion
- 2018-06
- Completion
- 2019-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Etoposide | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Icotinib | Small molecule | 125 mg | Oral |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |